0723 GMT - A late-stage trial showed that Roche's advanced breast cancer drug Itovebi not only delays disease progression but that these patients also live longer, Vontobel analyst Stefan Schneider says in a note. "Itovebi was already approved for first-line therapy on its primary endpoint last October and today's secondary endpoint reinforces that today," the analyst says. Vontobel leaves unchanged its 1.5 billion Swiss francs peak sales estimate for the drug in 2025.(helena.smolak@wsj.com)
(END) Dow Jones Newswires
January 28, 2025 02:24 ET (07:24 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。